Company: RNGE
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001641172-25-001343
Chunk: 1217

Company: RANGE IMPACT, INC.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 14
Chunk 1217
---

up to an additional 2,733,333 shares of the Company’s common stock at a price of $0.60 per share (the “April 2023 Warrants”).
The April 2023 Warrants expire on April 11, 2028. The aggregate proceeds to the Company from the sale of the April 2023 Shares and April
2023 Warrants were approximately $400,000.

In
August 2023, the Company entered into a securities purchase agreement providing for the issuance and sale by the Company of 6,666,667
shares of the Company’s common stock (the “August 2023 Shares”) at a price of $0.15 per share. After deducting for
fees and expenses, the aggregate net proceeds from the sale of the August 2023 Shares were approximately $1,000,000.

In
October 2023, the Company entered into warrant exchange agreements with certain holders of warrants to exchange warrants to purchase
a total of 21,733,334 shares of the Company’s common stock for an aggregate of 2,173,334 shares of the Company’s common stock.
The warrants that were exchanged were extinguished.

    F-15

In
December 2023, the Company entered into securities purchase agreements providing for the issuance and sale by the Company of 11,333,336
shares of the Company’s common stock (the “December 2023 Shares”) at a price of $0.15 per share. The aggregate proceeds
from the sale of the December 2023 Shares were approximately $1,700,000.

In
June 2024, the Company entered into securities purchase agreement providing for the issuance and sale by the Company of 3,703,704 shares
of the Company’s common stock (the “June 2024 Shares”) at a price of $0.27 per share. The aggregate proceeds
from the sale of the June 2024 Shares were approximately $1,000,000.

6.
STOCK OPTIONS

Stock
options issued during the year ended December 31, 2024

During
the year ended December 31, 2024, the Company granted to its Chief Financial Officer options to purchase an aggregate of 250,000
shares of the Company’s common stock with
exercise prices of $0.38
per share that expire ten
years from the date of grant. Half of the options
granted vested upon grant and the other half vests